UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP - PubMed (original) (raw)

. 2019 Jul;38(28):5686-5699.

doi: 10.1038/s41388-019-0822-6. Epub 2019 May 1.

Yi Huan 2, Jia Zheng 3, Ming Wei 4, Guoxu Zheng 5, Donghui Han 6, Jieheng Wu 7, Wenjin Xi 7, Feilong Wei 8, An-Gang Yang 7, Weijun Qin 9, He Wang 10, Weihong Wen 11

Affiliations

UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP

Dian Jiao et al. Oncogene. 2019 Jul.

Abstract

UHRF1 is an important epigenetic regulator that belongs to the UHRF family. Overexpression of UHRF1 has been found in many kinds of tumors and its overexpression is associated with poor prognosis and short survival in certain cancer types. However, its function in renal cell carcinoma (RCC) is not clear. Here we report that RCC tumor tissues had obviously higher UHRF1 expression than normal renal tissues. Downregulation of UHRF1 by siRNA or shRNA in RCC cell lines resulted in decreased cell viability, inhibited cell migration and invasion, and increased apoptosis. UHRF1 knockdown RCC xenografts also resulted in obviously inhibited tumor growth in vivo. After downregulation of UHRF1 in RCC cells, the expression of TXNIP was upregulated. In addition, after UHRF1 and TXNIP were simultaneously downregulated, cell viability and cell invasion increased, whereas cell apoptosis decreased compared with UHRF1 single downregulated cells. We also showed that UHRF1 could recruit HDAC1 to the TXNIP promoter and mediate the deacetylation of histone H3K9, resulting in the inhibition of TXNIP expression. Our results confirm that UHRF1 has oncogenic function in RCC and UHRF1 may promote tumor progression through epigenetic regulation of TXNIP. UHRF1 might be used as a therapeutic target for RCC treatment.

PubMed Disclaimer

References

    1. Genes Cancer. 2010 May;1(5):434-43 - PubMed
    1. Nature. 2007 Dec 6;450(7171):908-12 - PubMed
    1. Mol Cancer. 2014 Mar 19;13:62 - PubMed
    1. Lancet. 2009 Mar 28;373(9669):1119-32 - PubMed
    1. Cancer Sci. 2013 Feb;104(2):194-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources